Novo Nordisk has suffered noticeably in recent weeks - partly due to profit-taking after the massive rally, uncertainties surrounding production capacities for Wegovy/Ozempic and the general pressure on pharmaceutical and biotech shares. The recent weaker sales figures for individual GLP-1 products in the USA have also caused uncertainty. In short: the euphoria is gone, the share price is consolidating.
Nevertheless Novo remains my largest position - for good reason: the company has a structural growth market with its GLP-1 active ingredients. structural growth market Obesity and diabetes continue to increase globally, and Novo is at the forefront of this development. The pipeline is solid, the brand extremely strong and the margins speak for themselves. What currently looks like a dip is more of a healthy correction for me. healthy correction after a steep rise.
I expect Novo to continue to benefit from the global trend towards preventive healthcare and lifestyle therapy in the medium term - both medically and economically. If you take a long-term view, you currently have a strong player with a solid balance sheet, a fast-growing product line and still room for upside - especially after the setback.
